Abstract
Giant prolactinomas (gPRLomas) are rare tumors of the lactotroph defined by an unusually large size (>4 cm) and serum PRL levels >1000 ng/mL. The purpose of this study is to characterize the clinical spectrum of gPRLomas comparing them with non-giant prolactinomas. This is a retrospective study at a large referral center. Data from patients harboring gPRLomas and macroprolactinomas were retrieved from medical records of the Prolactinoma Clinic. Analysis was focused on clinical, biochemical, and tumor volume characteristics, as well as on the response to treatment with dopamine agonists. Among 292 patients with prolactinomas followed between 2008 and 2015, 47 (16 %) met the diagnostic criteria for gPRLomas (42 males). The most common complaint was a visual field defect; headache was reported by 79 % and sexual dysfunction was present in over half of the patients. Median basal PRL level and tumor volume were 6667 ng/mL (3750–10,000) and 32 cm3 (20–50), respectively; hypogonadotropic hypogonadism was documented in 87 %. Cabergoline treatment resulted in the normalization of PRL levels in 68 % and in the reduction of >50 % in tumor volume in 87 % of the gPRLoma patients. The composite goal of PRL normalization and >50 % tumor reduction was achieved by 55 % (n = 26) of patients with gPRL and by 66 % (n = 100) of patients with no giant macroprolactinomas (p = 0.19). Recovery of hypogonadism and improvement of visual fields defects occurred in 32 % and 68 % of the patients, respectively. Cabergoline treatment was equally effective in patients with gPRLoma and those with macroprolactinomas in regard of achieving treatment goals, although the median CBG dose was slightly higher in the gPRLoma group (2 vs. 1.5 mg/w). Six patients required surgery. Beyond their impressive dimensions and the huge amount of PRL they secrete, the clinical behavior of gPRLoma is not different from macroprolactinomas. These tumors are highly responsive to cabergoline treatment, and pituitary surgery is seldom required.
Similar content being viewed by others
References
A. Glezer, M. Bronstein, Prolactinomas. Endocrinol. Metab. Clin. North Am. 44, 71–78 (2015)
D. Maiter, E. Delgrange, Therapy of endocrine disease: the challenges in managing giant prolactinomas. Eur. J. Endocrinol. 170, R213–R227 (2014)
A.B. Moraes, C.S. Marques dos Santos, N.L. Vieira, M.R. Gadelha, Giant prolactinomas: the therapeutic approach. Clin. Endocrinol. (Oxf) 79, 447–456 (2013)
R. Shrivastava, M. Argenteanu, W. King, K. Post, Giant prolactinomas: clinical management and long-term follow up. J. Neurosurg. 97, 299–306 (2002)
M. Corsello, G. Ubertini, M. Altomare, R. Lovicu, M. Migneco, C. Rota, C. Colosimo, Giant prolactinomas in men: efficacy of cabergoline treatment. Clin. Endocrinol. (Oxf) 58, 662–670 (2003)
R. Care, V. Sunkaraneni, J. Theaker, P. Harries, Rapidly progressing giant invasive prolactinoma. J. Laryngol. Otol. 126, 840–843 (2012)
A. Siddiqui, N. Chew, K. Miszkiel, Unusual orbital invasion by a giant prolactinoma. Br. J. Radiol. 81, 259–262 (2008)
J. Steinberg, J. Cohen, J. Gomori, S. Fraifeld, S. Moscovici, G. Rosenthal, Y. Shoshan, E. Itshayek, Superficial siderosis of the central nervous system due to chronic hemorrhage from a giant invasive prolactinoma. J. Clin. Neurosci. 20, 1032–1034 (2013)
A. Wang, R. Mullan, M. Lane, A. Hazem, C. Prasad, N. Gathaiya, M. Fernández-Balsells, A. Bagattom, F. Coto-Yglesias, J. Carey, T. Elraiyah, P. Erwin, G. Gandhi, V. Montori, M. Hassan, Treatment of hyperprolactinemia: a systematic review and meta-analysis. Syst. Rev. 1, 33–54 (2012)
T. Ertekin, N. Acer, A.T. Turgut, K. Aycan, O. Ozcelik, M. Turgut, Comparison of three methods for the estimation of pituitary gland volume using magnetic resonance imaging: a stereological study. Pituitary 14, 31–38 (2011)
M.H. Almalki, B. Buhary, S. Alzahrani, F. Alshahrani, S. Alsherbeni, G. Alhowsawi, N. Aljohani, Giant prolactinomas: clinical manifestations and outcomes of 16 Arab cases. Pituitary 18, 405–409 (2015)
E. Delgrange, G. Raverot, M. Bex, P. Burman, B. Decoudier, F. Devuyst, U. Feldt-Rasmussen, M. Andersen, D. Maiter, Giant prolactinomas in women. Eur. J. Endocrinol. 170, 31–38 (2014)
M.P. Gillam, M.E. Molitch, G. Lombardi, A. Colao, Advances in the treatment of prolactinomas. Endocr. Rev. 27, 485–534 (2006)
E. Delgrange, J. Trouillas, D. Maiter, J. Donckier, J. Tourniaire, Sex-related difference in the growth of prolactinomas: a clinical and proliferation marker study. J. Clin. Endocrinol. Metab. 82, 2102–2107 (1997)
U. Kaiser, Hyperprolactinemia and infertility: new insights. J. Clin. Invest. 122, 3467–3468 (2012)
I. Shimon, C. Banbassat, M. Hadani, Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. Eur. J. Endocrinol. 165, 225–231 (2007)
I. Shimon, C. Benbassat, Male prolactinomas presenting with normal testosterone levels. Pituitary 17, 246–250 (2014)
M. Ono, N. Miki, T. Kawamata, R. Makino, K. Amano, T. Seki, O. Kubo, T. Hori, K. Takano, Prospective study of high-dose cabergoline treatment of prolactinomas in 150 patients. J. Clin. Endocrinol. Metab. 93, 4721–4727 (2008)
P. Iglesias, C. Bernal, C. Villabona, J.C. Castro, F. Arrieta, J.J. Diez, Prolactinomas in men: a multicentre and retrospective analysis of treatment outcome. Clin. Endocrinol. (Oxf) 77, 281–287 (2012)
L. Sibal, P. Ugwu, P. Kendall-Taylor, S.G. Ball, R.A. James, S.H. Pearce, K. Hall, R. Quinton, Medical therapy of macroprolactinomas in males: I. prevalence of hypopituitarism at diagnosis. II. proportion of cases exhibiting recovery of pituitary function. Pituitary 5, 243–246 (2002)
M.E. Molitch, Management of medically refractory prolactinoma. J. Neurooncol. 117, 421–428 (2014)
Acknowledgement
We are grateful to Dr. Mark E Molitch for his expert review of our manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors ES, EE, VM, CR, VM, and MM have no conflicts of interest to disclose.
Additional information
Etual Espinosa and Ernesto Sosa have contributed equally to this paper.
Rights and permissions
About this article
Cite this article
Espinosa, E., Sosa, E., Mendoza, V. et al. Giant prolactinomas: are they really different from ordinary macroprolactinomas?. Endocrine 52, 652–659 (2016). https://doi.org/10.1007/s12020-015-0791-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12020-015-0791-7